Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Tawbi
Hussein
H
University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, PA 15232, USA. tawbih@upmc.edu
Agarwala
Sanjiv S
SS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010793:Phthalazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D007211:Indoles
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D010793:Phthalazines; D011725:Pyridines; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; C404768:vatalanib; C500926:cediranib; D007211:Indoles